Ofatumumab in refractory chronic lymphocytic leukemia: experience through the French early access program. - Université Clermont Auvergne Accéder directement au contenu
Article Dans Une Revue Clinical Lymphoma, Myeloma & Leukemia Année : 2015

Ofatumumab in refractory chronic lymphocytic leukemia: experience through the French early access program.

Résumé

Background - The Autorisation Temporaire d'Utilisation (ATU) is an early access program available in France for drugs aimed at treating severe diseases not yet covered by a marketing authorization, for patients without any other therapeutic option and who cannot be included in a clinical trial. Patients and methods - This report presents the use of single-agent ofatumumab in 30 patients with advanced chronic lymphocytic leukemia (CLL) in the French ATU program. Results - These very-high-risk patients had received multiple previous treatments (median = 6), and most had disease that was fludarabine-refractory or alemtuzumab-refractory (or both) or was unsuitable for alemtuzumab treatment. In the intent-to-treat analysis, the overall response rate was 47% (4 of 30, complete response; 10 of 30, partial response). Of 13 patients with 17p deletion, 6 displayed response to ofatumumab, including 2 complete responses. Treatment was well tolerated, with 17 grade 3 or 4 adverse events; 4 cases of grade 3 or 4 infusion reactions were reported, with favorable immediate outcome. Among nonhematologic complications, infections were the most frequent. Conclusion - The results confirm the efficacy and acceptable tolerability profile of ofatumumab as a single agent in severely ill patients with CLL. Attention should be paid to possible early infusion reactions to ofatumumab, as well as to the risk of infection.

Domaines

Immunologie
Fichier non déposé

Dates et versions

hal-01162051 , version 1 (09-06-2015)

Identifiants

Citer

J Dupuis, P Brice, S François, Loic Ysebaert, S de Guibert, et al.. Ofatumumab in refractory chronic lymphocytic leukemia: experience through the French early access program.. Clinical Lymphoma, Myeloma & Leukemia, 2015, 15 (2), pp.e43-6. ⟨10.1016/j.clml.2014.07.013⟩. ⟨hal-01162051⟩
204 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More